Catalog5 refs
PE-22-28
Nootropic & NeuroCognitiveResearch use only
Educational use only. Not medical advice. Verify all information with primary sources and a licensed clinician before use.
Body Map
Overview
Synthetic heptapeptide derived from Spadin positions 22-28, functioning as potent TREK-1 antagonist with enhanced selectivity and duration versus parent compound. Selectively blocks TREK-1 potassium channels (IC50: 0.12 nM), enhancing serotonin neurotransmission in dorsal raphe nucleus, triggering CREB activation and hippocampal neurogenesis. 300-500x greater potency than full-length Spadin.
Primary Uses
Antidepressant-like effects
Cognitive enhancement
Mood improvement
Neuroprotection
BDNF upregulation
Hippocampal neurogenesis support
Rapid-acting antidepressant research
TREK-1 inhibition
Neurogenesis studies
Mood and cognition models
Rapid antidepressant effects
Anxiety reduction
Hippocampal neurogenesis
Synaptogenesis
Memory support
antidepressant
treatment-resistant depression
rapid onset mood effects
Protocol Reference
Dose
50–200 mcg daily
Frequency
Once Daily
Half-life
Not Well Characterized
Route
Subcutaneous
Evidence
Preclinical / Emerging (disputed)
Research References· 12
https://pubmed.ncbi.nlm.nih.gov/28955242/
PubMedPMID 28955242- [https://www.sciencedirect.com/science/article/pii/S0163725818301785](https://www.sciencedirect.com/science/article/pii/S0163725818301785)
COVID-19 and pregnancy: A European study on pre- and post-infection medication use↗
DOIEuropean Journal of Clinical Pharmacology2024Hurley E, Geisler B, Lupattelli A, et al.
Research Models
Mouserodents
Also in Nootropic & Neuro